poisar

Stocks · News reference

FDA Accepts Roche's Fenebrutinib NDA Under Priority Review For Relapsing And Primary Progressive MS, Backed By Phase III Data Showing 51.1%, 58.5% Relapse Reductions Vs Teriflunomide

Benzinga Newsdesk

Fenebrutinib cut relapses by 51% and 58% vs teriflunomide in Phase III RMS trials (FENhance 1 & 2) while showing a consistent, positive trend in delaying disability1Fenebrutinib became the first investigational

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

RHHBFRHHBYRHHVF
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  3. Benzinga Newsdesk

    Genentech's Giredestrant Plus Everolimus Cuts Risk Of Progression Or Death 44% In ITT And 62% In ESR1-Mutated ER-Positive Advanced Breast Cancer In Phase III EvERA; FDA Goal Dates Are Dec. 18 For Advanced Disease And Nov. 30 For Early-Stage Disease

    Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, versus standard endocrine therapy plus everolimusBy targeting resistance to

    RHHBFRHHBYRHHVF
  4. Delveinsight

    Type 2 Diabetes Market to Grow Significantly During the Forecast Period (2026–2036), with Rising Prevalence and Increasing Uptake of Next-Generation Therapies | DelveInsight

    The type 2 diabetes market is projected to experience steady growth through 2036, driven by rising global prevalence, obesity, and adoption of next-generation therapies including GLP-1 receptor agonists and SGLT2 inhibitors. Key emerging drugs from major pharmaceutical companies like Novo Nordisk, Eli Lilly, and Boehringer Ingelheim are expected to reshape the market landscape with improved glycemic control and weight management benefits.

    NVOLLYRHHBYALNYIVBIY
  5. Researchandmarkets.Com

    Europe Point of Care Diagnostics Market Size and Forecast, 2021 - 2031 | Market to Reach US$21.4 Billion by 2031 as Rapid Testing and Molecular Innovation Drive 13.4% CAGR

    Europe's Point of Care (POC) Diagnostics Market is projected to grow from US$8.9 billion in 2024 to US$21.4 billion by 2031, with a 13.4% CAGR driven by rapid testing innovation, molecular diagnostics advancement, and increasing prevalence of infectious and chronic diseases. Germany leads the regional market, supported by strong healthcare infrastructure and public health initiatives. Key players include Siemens AG, Abbott Laboratories, Roche, bioMerieux, Bio-Rad, QIAGEN, Nova Biomedical, Polymer Technology Systems, and Danaher Corp.

    ABTRHHBYBIOBIO.BQGEN
  6. Researchandmarkets.Com

    Immunogenomics Market Size, Share, Trends, and Growth Forecast, 2026-2033 | NGS and Personalized Medicine Drive Market Toward USD 9.82 Billion at 5.97% CAGR

    The global immunogenomics market is projected to grow from USD 6.32 billion in 2025 to USD 9.82 billion by 2033, expanding at a CAGR of 5.97%. Growth is driven by advancements in next-generation sequencing technologies, increasing demand for personalized medicine, and rising prevalence of immune-related disorders. Key applications include oncology, infectious disease research, vaccine development, and autoimmune disorder studies, with adoption across hospitals, diagnostic laboratories, pharmaceutical companies, and academic institutions.

    TMOILMNQGENRHHBYA